









Markets
/
Stocks
/
nasdaq-silo
/

Silo Pharma Inc

SILO

0.306USD

+0.019+6.55%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.20MMarket Cap

LossP/E TTM



Silo Pharma Inc

0.306

+0.019+6.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Silo Pharma Inc

Currency: USD Updated: 2026-02-06

Key Insights

Silo Pharma Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 124 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Silo Pharma Inc's Score

Industry at a Glance

Industry Ranking

124 / 159

Overall Ranking

446 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Silo Pharma Inc Highlights

StrengthsRisks

Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.

Growing

The company is in a growing phase, with the latest annual income totaling USD 72.10K.

Overvalued

The company’s latest PE is -0.34, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.56M shares, increasing 40.16% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 24.32K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.79.

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Silo Pharma Inc is 6.46, ranking 144 out of 159 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 18.02K, representing a year-over-year increase of 0.00%, while its net profit experienced a year-over-year increase of 19.55%.

Score

Industry at a Glance

Previous score

6.46

Change



Financials

9.27

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.64

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Silo Pharma Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Silo Pharma Inc is 8.19, ranking 25 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.34, which is -6.14% below the recent high of -0.32 and -776.88% above the recent low of -2.94.

Score

Industry at a Glance

Previous score

8.19

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 124/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for Silo Pharma Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Silo Pharma Inc is 5.45, ranking 139 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 0.39 and the support level at 0.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.29

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Sell

RSI(14)

36.266

Neutral

STOCH(KDJ)(9,3,3)

21.435

Buy

ATR(14)

0.031

High Vlolatility

CCI(14)

-114.523

Sell

Williams %R

70.460

Sell

TRIX(12,20)

-0.724

Sell

StochRSI(14)

91.699

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.310

Sell

MA10

0.332

Sell

MA20

0.355

Sell

MA50

0.386

Sell

MA100

0.486

Sell

MA200

0.573

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Silo Pharma Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 11.68%, representing a quarter-over-quarter increase of 164.88%. The largest institutional shareholder is The Vanguard, holding a total of 24.32K shares, representing 0.18% of shares outstanding, with 49.86% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Anson Funds Management LP.

952.38K

SEG Opportunity Fund LLC

952.08K

-0.03%

Intracoastal Capital, L.L.C.

702.91K

-16.79%

AdvisorShares Investments, LLC

364.88K

+98.05%

Weisblum (Eric)

216.93K

+2.36%

Virtu Americas LLC

107.79K

Geode Capital Management, L.L.C.

39.60K

+0.74%

The Vanguard Group, Inc.

Star Investors

16.33K

Jane Street Capital, L.L.C.

16.77K

Two Sigma Investments, LP

16.47K

-61.89%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Silo Pharma Inc is 1.90, ranking 142 out of 159 in the Pharmaceuticals industry. The company's beta value is 0.64. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.